Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1175 - Efficacy and tolerability of first-line chemotherapy in elderly patients (age ≥70 years) with metastatic gastric cancer: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)


08 Oct 2016


Poster Display


Mehmet Aldemir


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


M.N. Aldemir1, M. Turkeli2, B. Hacioglu3, A. Sakin4, E. Yaman5, E. Coban6, D. Koca7, M. Karaca8, M. Simsek2, A. Bahceci9, E. Sen10, T. Eren11, B.Ö. Aliustaoglu12, T. Sakalar13, N.O. Kalkan14, G. Aktas15, M. Bilici2, S. Turhal16, M. Benekli8, S.B. Tekin2

Author affiliations

  • 1 Medical Oncology, Ataturk University Medical Faculty, 25242 - Erzurum/TR
  • 2 Medical Oncology, Ataturk University Medical Faculty, Erzurum/TR
  • 3 Medical Oncology, Trakya University Rektörlüğü, Edirne/TR
  • 4 Medical Oncology, S.B. Okmeydani Education And Research Hospital, Istanbul/TR
  • 5 Medical Oncology, Mersin University School of Medicine, Mersin/TR
  • 6 Medical Oncology, Bezmialem Vakif University Hospital, Istanbul/TR
  • 7 Medical Oncology, Medical Park Hospital, Kocaeli/TR
  • 8 Medical Oncology, GUTF (Gazi Üniversitesi Tip Fakültesi)-Gazi University Faculty of Medicine, Ankara/TR
  • 9 Medical Oncology, Cumhuriyet University Hospital, Sivas/TR
  • 10 Medical Oncology, Selcuk University Meram Medical Faculty, Konya/TR
  • 11 Medical Oncology, Diskapi Yıldırım Beyazıt Teaching and Research Hospital, Ankara/TR
  • 12 Medical Oncology, Haydarpasa Numune Education and Research Hospital, Istanbul/TR
  • 13 Medical Oncology, Erciyes University Medical Faculty M.Kemal Dedeman, Oncology Hospital, Kayseri/TR
  • 14 Medical Oncology, Yuzuncu Yil University Medical Faculty, Van/TR
  • 15 Medical Oncology, Gaziantep University Onkoloji Hastanesi, Gaziantep/TR
  • 16 Medical Oncology, Anadolu Medical Center, Kocaeli/TR


Abstract 1175


Gastric cancer that is generally diagnosed in advanced stages is the second leading cause of cancer-related death worldwide. Although chemotherapy has benefit on quality of life and overall survival (OS) in metastatic gastric cancer (MGC), OS usually remains less than a year. Here, the efficacy and tolerability of first-line chemotherapy in MGC patients aged 70 years and older was investigated


As a multicenter study of ASMO, 305 patients followed in 17 centers between 2005 and 2015 were included. Patients who were 70 years and older at the time of MGC diagnosis and who had received at least two cycles of chemotherapy in the first-line setting were evaluated retrospectively.


The clinical and demographical features of the patients were presented in Table 1. Median age was 73 (min-max 70-90). Median follow-up time was determined as 8 months (min-max 1-78), median PFS as 6 months (95%CI: 5.2-6.7) and median OS as 10 months (95%CI: 8.4-11.6). Partial response was achieved in 26.2% and stable disease in 16.7% of the patients. The most common chemotherapy related grade 3-4 hematologic toxicity was neutropenia (22%). Poor ECOG performance status, history of surgical treatment and less number of metastatic organs had statistically significant benefit on PFS and OS (p 


We observed that first-line chemotherapy was effective and tolerable in elderly patients. The chemotherapy regimen (multiple or single) and the dose reduction at the beginning did not affect treatment response. It is reasonable to choose the minimum toxic and maximum tolerable chemotherapy regimen. It will be more relevant to use physiological age evaluations like ECOG performance status than biological age in treatment decision.

Clinical trial identification

Legal entity responsible for the study

Anatolian Society of Medical Oncology (ASMO)




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings